Status:
UNKNOWN
Association Between Time in Range and In-hospital Outcomes in Type 2 Diabetic Patients With Acute Coronary Syndrome
Lead Sponsor:
Ningbo No. 1 Hospital
Conditions:
Type 2 Diabetes Mellitus
Acute Coronary Syndrome
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The aim of this study is to use real-time continuous glucose monitoring (real-time CGM) system to get a 14-days blood glucose profile of the hospitalized type 2 diabetes mellitus (T2DM) patients with ...
Eligibility Criteria
Inclusion
- aged ≥18 and ≤70 years old;
- T2DM according to 2022 American Diabetes Association standards;
- Patients admitted to hospital with either non-ST elevation acute coronary syndrome or ST-elevation myocardial infarction; coronary angiography examination data can be collected;
- a stable glucose lowering regimen for the previous 3 months;
- obtain informed consent;
- with complete clinical data.
Exclusion
- Diagnosis of other types of diabetes, such as type 1 diabetes, gestational diabetes, secondary diabetes, etc.;
- No acute complications of diabetes, such as ketoacidosis, nonketotic hyperosmolar coma, etc.;
- Repeated severe hypoglycemia or hyperglycemia in the past 3 months;
- Patients who have had a history of allergic reactions to CGM materials or skin adhesives, alcohol or chlorhexidine disinfectants;
- Patients who have symptoms and signs of skin lesions, scarring, redness, infection or edema at the sensor application site that can affect the accuracy of sensor application or interstitial fluid glucose measurements;
- Combined with other acute disease states, such as uncontrolled severe infection, use of catecholamines or sedatives, use of ventilator, ventricular fibrillation, etc.;
- Patients who have a history of hematocrit, platelet, and hemoglobin abnormalities within past 2 months; moderate to severe anemia; or a disease (such as a coagulation disorder) that increases the risk of bleeding;
- Patients with malignant tumors, severe liver and kidney diseases, allergic diseases, mental and neurological diseases, combined with rheumatic or immune diseases;
- Using drugs that may affect blood sugar, including steroids, psychotropic drugs, anti-AIDS drugs, etc.;
- X-ray, CT, MRI examinations are scheduled during the period of wearing the sensor, and the appointment time cannot be changed to the beginning or the end of wearing;
- Patients currently participate in another clinical trial;
- Unwilling or unwilling to comply with study requirements, poor compliance, or refusal to use real time-CGM.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05389254
Start Date
June 1 2022
End Date
December 1 2023
Last Update
May 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ningbo First Hospital
Ningbo, Zhejiang, China, 315000